Related Experiment Videos

Human umbilical vein for vascular access in chronic hemodialysis

Insights

Human umbilical vein grafts provide a viable vascular access for hemodialysis in chronic renal failure patients. Despite complications like infection and thrombosis, these grafts offer a functional option when other methods fail.

Area of Science:

  • Vascular Surgery
  • Nephrology
  • Biomaterials

Background:

  • Chronic renal failure necessitates reliable vascular access for hemodialysis.
  • Conventional vascular access methods (e.g., arteriovenous fistulas) may not always be feasible.
  • Human umbilical vein grafts (HUVS) have been utilized as an alternative access method since 1979.

Purpose of the Study:

  • To evaluate the efficacy and complications of human umbilical vein grafts for hemodialysis access.
  • To determine the long-term function and patency rates of HUVS in patients with end-stage renal disease.

Main Methods:

  • A retrospective analysis of 33 HUVS fistulas implanted in 24 patients undergoing hemodialysis.
  • Documentation of implantation, complications (infection, thrombosis, aneurysm, stenosis), interventions, and graft survival.
  • Assessment of functional duration and patency rates.

Main Results:

  • A median graft function time of 8.5 months was achieved in 26 utilized grafts.
  • Complications included infection (7/33 grafts, all removed), thrombosis (25/33 grafts, 5 lost, 20 successful thrombectomies), aneurysm (4/33 grafts, 2 lost), and stenosis (3/33 grafts, 1 lost).
  • At study end, 10 grafts remained open, with 8 actively used for hemodialysis.

Conclusions:

  • Human umbilical vein grafts represent an acceptable vascular access option for hemodialysis.
  • HUVS can provide functional access, particularly when standard fistula creation methods are exhausted.
  • Careful monitoring is required due to potential complications such as infection and thrombosis.

Related Concept Videos